17 results on '"Niccoli P"'
Search Results
2. Caractérisation cliniques et pathologiques des tumeurs neuroendocrines rénales : une étude nationale rétrospective du Groupe des Tumeurs Endocrines (GTE)
3. 567O First International Randomized Study in Malignant Progressive Pheochromocytoma and Paragangliomas (FIRSTMAPPP): An academic double-blind trial investigating sunitinib
4. 7O Updated results from phase I study of CC-90011 in patients (pts) with solid tumours (STs), including neuroendocrine neoplasms (NENs), and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
5. 528O CC-90011 in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study
6. 18O CC-90011 in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study
7. AcSé immunotherapy trials: Anti-PD-1 therapy for adult patients with selected rare cancer types
8. Étude pronostique des phéochromocytomes et paragangliomes malins (étude MAPP-Prono) : étude rétrospective des réseaux COMETE et ENSAT
9. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study
10. Mapp-prono : étude européenne rétrospective pronostique des phéochromocytomes et paragangliomes malins
11. Treatment Satisfaction, Symptom Control, and Quality of Life (Qol) with Lanreotide Autogel (Lan) in Neuroendocrine Tumour (Net) Patients with Carcinoid Syndrome (Cs): Results from the Symnet Study
12. Paragangliome médiastinal sécrétant, dans le cadre d’une maladie de Von Hippel Lindau : mise en évidence d’une nouvelle mutation du gène VHL
13. Le dosage ultrasensible de calcitonine basale peut-il remplacer le test à la pentagastrine ?
14. Updated Overall Survival (OS) Analysis from a Phase III Study of Sunitinib vs Placebo in Patients (PTS) with Advanced, Unresectable Pancreatic Neuroendocrine Tumor (NET)
15. 6569 POSTER Updated Overall Survival Data From a Phase III Study of Sunltlnlb Vs. Placebo in Patients With Advanced, Unresectable Pancreatic Neuroendocrine Tumour (NET)
16. Le réseau national de référence pour la prise en charge des tumeurs (neuro-) endocrines malignes rares sporadiques et héréditaires (RENATEN). Réseau labellisé par l’INCa
17. 6501 Sunitinib (SU) vs placebo for treatment of progressive, well- differentiated pancreatic islet cell tumours: results of a phase III, randomised, double-blind trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.